Chemistries of bifunctional PROTAC degraders

Cao, Chaoguo, He, Ming, Wang, Liguo, He, Yuna, Rao, Yu·2022·Chemical Society Reviews

DOI 10.1039/d2cs00220e

Cited by (315)

Items 201–300 of 315

Modular Assembled Targeting Chimera Enables Multimodal Targeted Protein Degradation
Wentao Zhu, Wenqian Zhang, Yinmiao Wang, Jian Chen, Fang Xu, Jiyan Pang · 2025 · JACS Au
Bioorthogonal Sonodynamic Plug‐and‐Play Targeting Chimeras (SDPTAC) for Precise Targeted Protein Degradation
Yuhan Bao, Yaojin Zhu, Xinhao Wei, Yuxin Fang, Jiayi Zhu, Fei Gao, Guoqiang Dong, Shipeng He, Chunquan Sheng · 2025 · Advanced Science
Ginsenoside Rh2- functionalized liposomes enhanced BRD4-PROTAC delivery and antitumor efficacy via improved tumor targeting and ECM remodeling
Lijuan Wen, Jialei Rao, Jiaoting Chen, Fang Li, Xixi Chen, Shenpeng Guo, Binghui Cui, 邱财生, Weiliang Chen · 2026 · Materials Today Bio
Unveiling a new strategy for PDIA1 inhibition: Integration of activity-based probes profiling and targeted degradation
Bei Zhang, Dawei Hong, Hujuan Qian, Keqing Ma, Liquan Zhu, Linye Jiang, Jingyan Ge · 2024 · Bioorganic Chemistry
Correlation between Membrane Permeability and the Intracellular Degradation Activity of Proteolysis-Targeting Chimeras
Hidetomo Yokoo, Hinata Osawa, Kosuke Saito, Yosuke Demizu · 2024 · Chemical and Pharmaceutical Bulletin
Rapid and high-throughput screening of proteolysis targeting chimeras using a dual-reporter system expressing fluorescence protein and luciferase
Shuai Meng, Yuan Meng, Xuena Yang, Wenwen Yu, Bole Li, Tianjun Liu, Jie Zhang, Xiubao Ren, Lin Zhang · 2025 · BMC Biology
Design, synthesis, and biological evaluation of RIPK1-targeting PROTACs
Hefeng Zhang, Shuonan Zhang, Tianchen Wang, Yaohan Lan, Yang Dai, Xia Peng, Yuxiang An, Xue Yi, Jing Ai, Wenhu Duan · 2025 · Molecular Diversity
The Discovery of a Specific CKIP-1 Ligand for the Potential Treatment of Disuse Osteoporosis
Yange Wei, Bo Wu, Mingqiu Liu, Chun‐Ping Cui · 2024 · International Journal of Molecular Sciences
Facile Synthesis of Homodimeric Protein Ligands
Weijun Gui, Thomas J. Kodadek · 2023 · ChemBioChem
Rapid PROTAC discovery platform: nanomole scale array synthesis and direct screening of reaction mixtures to facilitate the expedited discovery and follow-up of PROTAC hits.
Mateusz P. Plesniak, Emilia K. Taylor, Frederik Eisele, Christopher M. B. K. Kourra, Iacovos N. Michaelides, Alice Oram, Johan Wernevik, Zulma Santisteban Valencia, Hannah Rowbottom, Nadia Mann et al. · 2023 · ChemRxiv
Continuous Flow Synthesis of Amides in Bio-Derived Solvent GVL
Xu-Yang Mu, Rui Zhu, Li-Jie Yu, Wenlong Wang · 2024 · Letters in Organic Chemistry
Unveiling New Triazoloquinoxaline‐Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9
Martina Pierri, Guglielmo Bove, Erica Gazzillo, Ester Colarusso, Francesca Scala, Giacomo Pepe, Stefania Terracciano, Maria Giovanna Chini, Nicla Simonelli, Ines Bruno et al. · 2025 · Chemistry - A European Journal
Research progress of dual-targeting CDKs regulators for cancer therapy
Fei-Xia Yue, Yalan Wang, Rui-Yan, Guoqing Chen, Xiaoting Li, Qing‐Kun Shen · 2025 · Bioorganic Chemistry
De Novo Design of Hexamer‐Linker Dual‐Action Nano‐PROTAC for Tumor‐Specific Ferroptosis
Ni‐Yuan Zhang, Zhuan Wen, Ming‐Ze Cai, Ke‐Ting Zhou, Hao‐Ze Li, Yixuan Liu, Shang Wei Wu, Yu Xia, Hong‐Wei An, Hao Wang · 2025 · Angewandte Chemie
Split‐Deliver‐Click: Tumor‐Specific Protein Degradation via “AND” Logic‐Gated In‐Cell Bioorthogonal Clicking of PROTACs
He Dong, Cilong Chu, Ihsan Ullah, Qing Xu, Zhenhai Pan, Youyong Yuan · 2026 · Angewandte Chemie
Proteolysis-targeting chimera (PROTAC) in cancer: design principles and applications on “undruggable” targets
Xun Lu, Jianliang Qin, Shuilin Dong, Yue Yuan, Zhanguo Zhang, B Zhang, Xiaoping Chen, Xiaoli Gan, Huifang Liang, Furong Liu · 2026 · Biomarker Research
Pretargeted PROTAC Strategy Enables Precise Tumor Target Degradation via Self-Assembling Peptides
Qianqian Wu, Chen Zhang, Yuanheng Li, Miao Zhang, Hao Yan, Naihan Xu, Chunyan Tan, Ying Tan · 2026 · ACS Applied Materials & Interfaces
A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II Inhibition
Ji Hyeon Kim, Caitlin E. Mills, Zuzanna Kozicka, Daniel C. Scott, Cyrus Jin, Zixuan Jiang, Brendan G. Dwyer, Qixiang Geng, Sean T. Toenjes, Woong Sub Byun et al. · 2026 · Journal of the American Chemical Society
The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer
Xin Lin, Hua Xiang, Guoshun Luo · 2026 · Drug Discovery Today
Efficient, multi-hundred-gram scale access to E3 ubiquitin ligase ligands for degrader development
Mark S. Cooper, Mark C. Norley, Simon Armitage, Joel O. Cresser-Brown, Anthony K. Edmonds, Sean Goggins, Jonathan P. Hopewell, Burhan Karadogan, Kevin A. Knights, Toby J. Nash et al. · 2023 · Organic & Biomolecular Chemistry
Design and evaluation of anaplastic lymphoma kinase degraders using a covalent fumarate handle
Namsik Yu, Ji‐Eun Lee, Seulki Park, Su Kyeong Yun, Do Hyun Ryu, Jung‐Ae Kim, Jeong‐Hoon Kim, Jong Yeon Hwang · 2024 · Bioorganic & Medicinal Chemistry Letters
Spatiotemporally Controllable Covalent Bonding of RNA for Multi‐Protein Interference
Hao Fang, Tingting Wang, Jun Dai, Jingjing Hu, Zhaojun Chen, Lizhen Yuan, Yuning Hong, Fan Xia, Xiaoding Lou · 2024 · Advanced Healthcare Materials
Enzyme‐Activated Orthogonal Proteolysis Chimeras for Tumor Microenvironment‐Responsive Immunomodulation
Caixia Sun, Songhan Liu, Jun Wei Lau, Hanyu Yang, Yun Chen, Bengang Xing · 2025 · Angewandte Chemie
Transcription factor degraders
Manni Wang, Yuhao Wei, Xiaoling Ma · 2025 · Elsevier eBooks
HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking
Shipeng He, Wenjing Huang, Yaojin Zhu, Fei Gao, Yuxin Fang, Jiayi Zhu, Yuhan Bao, Guoqiang Dong, Chunquan Sheng · 2025 · Angewandte Chemie
Synthesis and degradation effect of PROTACs targeting EGFR triple mutants
Xiao-Xiao Xi, Hongyi Zhao, Minhang Xin, Shuai Mao, San‐Qi Zhang · 2025 · Bioorganic & Medicinal Chemistry
PROTACs as novel therapeutics against Mycobacterium tuberculosis: Current progress and future directions
Deepthi Ramesh, Ahammed Ameen Thottasseri · 2026 · European Journal of Medicinal Chemistry
PROTAC-based protein degradation: a window of opportunity for melanoma therapy
Giulia Gentile, Simona D’Aguanno, Marta Di Martile, Adele Petricca, Elisabetta Valentini, Stefano Scalera, Donatella Del Bufalo · 2026 · Journal of Biomedical Science
Design, synthesis, and pharmacological evaluation of novel PROTAC degraders targeting 11β-HSD1 for metabolic disease intervention
Liguo Wang, Xue Tao, Ming He, Yu Lu, Yuji Wang, Juanjuan Zhu · 2026 · Bioorganic Chemistry
Autonomously Motile Nano‐PROTACs Act as Protein‐Sweeping Robots to Enhance Targeted Protein Degradation
Xiang Yang Lu, Furui Qiu, Huijie Liang, Xiaomin Wang, Meng Xue, Jianghao Wang, Jinjin Shi, Hongling Zhang, B L Wang · 2026 · Advanced Materials
Discovery of Effective Dual PROTAC Degraders with Synergistic Antitumor Activity for Overcoming Tamoxifen-Resistant Breast Cancer
Lilan Xin, Jing Liu, Xinyi Guo, S Li, Zhangxiao Guo, Hongli Wang, Zemin Song, Xiaofei Deng, C Wang, P H Fang et al. · 2026 · Journal of Medicinal Chemistry
RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1
Chang Shen, HD Sun, Ruining Li, Raghupathi Mutyala, Xinjian Tian, Chaoqun Huang, Jinglei Hu, Jie An, Lin Li, Tao Zhang et al. · 2026 · Journal of Medicinal Chemistry
Programmable nanomedicine via bioorthogonal molecular engineering
Sunwoo Im, Seyoung Koo, Jong Seung Kim · 2026 · Nano Convergence
Feasibility and Advantages of Designing Proteolysis Targeting Chimeras Targeting Peroxisome Proliferator-activated Receptors for Cancer Treatment
Sihan Zhang, Zhipeng Yao, Na Zeng, Zheng Liu, Qi‐Dong Xia, Shao-Gang Wang · 2024 · Exploratory Research and Hypothesis in Medicine
PROTACs in the Management of Prostate Cancer
Deepa S. Mandlik, Satish K. Mandlik · 2024 · Springer eBooks
Discovery of Alkenyl Oxindole as a Novel PROTAC Moiety for Targeted Protein Degradation via CRL4 DCAF11 Recruitment
Ying Wanga, Tianzi Wei, Man Zhao, Aima Huang, Fan Sun, Lu Chen, Risheng Lin, Yubao Xie, Ming Zhang, Shiyu Xu et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation
Rong Zheng, Abhay Prasad, Deeksha Satyabola, Yang Xu, Hao Yan · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
Degradation of intrinsically disordered proteins using proteolysis targeting nanobody conjugate
Xiaofeng Sun, Dinglan Wu, Chengjian Zhou, Simin Xia, Xi Chen · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
Proteolysis‐Targeting Chimeras (PROTACs)
Liang Shen · 2025
De novo designed bifunctional proteins for targeted protein degradation
Bram Mylemans, Bogusława Korona, Amanda M. Acevedo‐Jake, Ailsa MacRae, Thomas A. Edwards, Danny T. C. Huang, Andrew John Wilson, Laura S. Itzhaki, Derek N. Woolfson · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
Ruthenium-catalysed C‒H amidation for the late-stage synthesis of PROTACs
Daniele Antermite, Stig D. Friis, Johan R. Johansson, Okky Dwichandra Putra, Lutz Ackermann, Magnus J. Johansson · 2023 · ChemRxiv
Computational strategies for the design of proteolysis targeting chimera degraders: Artificial intelligence enabled PROTAC design
Rajamanikkam Kamaraj, Radim Nencka, Petr Pávek · 2024 · Annual reports in medicinal chemistry
Discovery of the First Potent Ror1 Degrader for the Treatment of Non-Small Cell Lung Cancer
Fengtao Zhou, Jinlin Li, Lin Li, Caiyun Hou, Zhaodi Tian, Yang Zhou, Jinwei Zhang, Xiaomei Ren, Zhen Wang, Weixue Huang et al. · 2024 · SSRN Electronic Journal
Integrating PROTAC technology with natural product research: A new frontier in target identification
Baoyu Wei, Jinyun Dong, Yi Liang, Jiang‐Jiang Qin, Guoyin Kai · 2025 · Elsevier eBooks
Harnessing the power of traditional Chinese medicine for targeted protein degradation
Zheng Wu, Bo Zhu, Yiwen Shou, Hongwei Guo · 2025 · Elsevier eBooks
The Functions and Regulatory Chemicals of Human Leucine Zipper Transcription Factors (LZ TFs)
Hanming Yang, Shuyang Bi, Biao Yu, Pengfei Fang, Jing Wang · 2025 · 化学学报
Degradation of Cyclin-Dependent Kinase: A New Weapon for Cancer Therapy
Xing Tian, Xiaojie Dai, Ye Zhong, Maosheng Cheng, Yang Liu · 2025 · Pharmaceutical Fronts
Surf2Spot: A Surface-Informed Geometry-Aware Model for Predicting Binder and Nanobody Design Hotspots
Anwen Zhao, Yu Li, Tianhao Wu, Ran Fu, Zixuan Wang, Yanfen Xu, Xuliang Han, Yuxuan Lou, Wenying Wang, Jun Yan et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
Synthesis and anticancer activity of parthenolide-based PROTACs for IKKβ degradation
Zhenxi Su, Yiwu Wu, Yijie Su, Yuhan He, Jieyin Liu, Deng‐Gao Zhao · 2026 · Bioorganic & Medicinal Chemistry Letters
Efficient green synthesis of the targeted proteolysis system component
Maria Zakharova, М. В. Чудинов, Maxim E. Zhuravlev, Alexei Lukin · 2026 · Mendeleev Communications
Design and Synthesis of Pyrrolo[3,4- d ]pyrimidine-Based ATR Degraders for Effective Treatment of Colorectal Cancer in Mouse Model
Nian‐Dong Mao, Zi Hui, Chen-Chen Wang, Meng-Lan He, Shun-Ran Li, Meng-Qian Yu, Lulu Ye, Jiawei Zhou, Zong-Hao Wang, Bo-Qun Du et al. · 2026 · Journal of Medicinal Chemistry
Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications
Jiaye Wen, Jingtian Yu, Wuqiang Wen, Baishan Jiang · 2026 · MedComm – Oncology
Kinase degrader: a new era of drug development
Chao Zhang, Yu Rao · 2026 · Elsevier eBooks
Targeting taurine metabolism via PROTAC-mediated SLC6A6 degradation potentiates photodynamic therapy and reverses immunosuppression in cholangiocarcinoma
Jingjin Zhu, Tianhao Zou, Weimin Wang, Jianjun Xu, Xuan Li, Lei Liu, Bohan Yang, Zifang Song, Yang Gao · 2026 · Journal of Nanobiotechnology
Design, synthesis, and biological evaluation of HSP70-mediated HEMTACs as novel androgen receptor degraders
Zhenzhen Li, Xinru Han, Shuxian Guo, Lüpei Du · 2026 · European Journal of Medicinal Chemistry
PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy
Ruiling Xu, Xiaowen Han, Yunfei Sun, Chaofan Ma, Shuqing Liao, Ruo Tang, Yinquan Pu, Xueting Zheng, Jie Zhang, Wen Yang et al. · 2026 · Materials Today Bio
Microneedle‐Assisted Systems for the Delivery of Proteolysis Targeting Chimeras (PROTACs)
Pooja Tiwary, Krishil Oswal, Aishwarya Shirke, Heena V. Maithania, Ryan Varghese, Lalitkumar K. Vora · 2026 · Advanced Therapeutics
Discovery of a potent PROTAC targeting G9a suppresses proliferation of triple-negative breast cancer cells and psoriasis-like keratinocytes
Mingxia Liu, Lian Wang, Zhaoping Pan, Jing Ye, Fengbo Wu, Gu He, Yujuan Chen · 2026 · European Journal of Medicinal Chemistry
Integrative structural and computational analysis reveals potential design principles for efficient PROTAC degraders
Yi Zhou, Yu Cao, Xinyue Ma, Hao Yang, Siyuan Tian, Chenjia Zhu, Yilin Tang, Ran Zhang, José N. Onuchic, Fang Bai · 2026 · Cell Reports Physical Science
Sprayable androgen receptor PROTAC degrader for immunomodulation and accelerated skin regeneration
Se Youn Jang, Byeongmin Park, Eunbyeol Ko, 신동원, Yeongji Jang, Won Suk Lee, Jae-Hyeon Lee, Ansoo Lee, Jooho Park, S P Lee et al. · 2026 · Chemical Engineering Journal
Discovery of novel cereblon-recruiting PRMT5 degraders with in vivo efficacy against triple-negative breast cancer
Yuzhan Li, Yaxun Guo, Dazhao Mi, Fubing Li, Jingfeng Song, Qiansen Zhang, Ceshi Chen, Zhigang Yu, Yihua Chen · 2026 · European Journal of Medicinal Chemistry
Development of Hydrophobic Tag Based HDAC6 Degrader for Ulcerative Colitis Treatment
Daoran Lu, Rongfeng Liu, Congcong Zheng, Yueyi Sun, Jianjun Gao, Yepeng Luan · 2026 · Journal of Medicinal Chemistry
De Novo-Designed Bifunctional Proteins for Targeted Protein Degradation
Bram Mylemans, Bogusława Korona, Amanda M. Acevedo‐Jake, Ailsa MacRae, Thomas A. Edwards, Danny T Huang, Andrew John Wilson, Laura S. Itzhaki, Derek N. Woolfson · 2026 · Journal of the American Chemical Society
A review of deep learning-based molecular generation
Meiling Xu, Haoyuan Song, Yaguo Dong · 2026 · Neurocomputing
Discovery of BRD9 PROTAC/IMiD Bifunctional Molecules as Potent Therapeutics for Hematologic Malignancies
Haiting Duan, Ruoxin Chen, Jingyu Zhang, Huan Zhou, Bizhi Li, Xiangying Zhai, Hanlin Wang, Rongkuan Jiang, Jiangzhou Song, Jia Li et al. · 2026 · Journal of Medicinal Chemistry
Transdermal STING Degradation Reprograms Innate‐Adaptive Immunity Crosstalk for Relapse‐Free Psoriasis and Comorbid Arthritis Therapy
Mengchao Ding, Zhenhai Pan, Ihsan Ullah, Ye Liu, Songke Shen, Mohamed E. El‐Khouly, Youyong Yuan · 2026 · Advanced Functional Materials
Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader
Yuehui Li, Yu Du, Ping Deng, Yi Yang, Yue Wu, Xiaomeng Sun, Qiuzhu Chen, Juntong Yang, Qihua Zhu, Zongjie Gan et al. · 2026 · Bioorganic Chemistry
Proteolysis-Targeting Chimera-Loaded Hydrogel Dressings Orchestrate Immunoregulation and Angiogenesis to Promote Tissue Regeneration in Large Diabetic Wounds
Wenjun Yang, Yandong Zhao, Minjian Liao, Xiuju Fang, Ahmed M. M. Alazaly, Youyong Yuan, Rui Guo · 2026 · Acta Biomaterialia
Hsc70-Mediated Targeting Chimeras for Targeted Protein Degradation via Chaperone-Mediated Autophagy
Chao Chen, Ying Zheng, Xiuyu Tao, Liya Yang, Chaoyue Wang, Xiaoqian Liu, Ruixi Zhao, Haokang Ding, Peng Sun, Haotian Liu et al. · 2026 · Journal of Medicinal Chemistry
Branched DNA Nanoplatform-Based Multivalent PROTACs for Tumor Microenvironment-Responsive Degradation of Telomere-Binding Proteins in Tumor Therapy
Hanyin Zhu, Xintong Li, Hong Wang, Huarui Liu, Dandan Li, Changping Yang, Baoquan Ding, Jianbing Liu · 2026 · Nano Letters
Targeted dual degradation of GPC-3 and VEGFR with multivalent DNA nanoflower-based LYTACs for hepatocellular carcinoma therapy
Ping Zhou, Jinzhi Zang, Jiaxuan Wang, Minghui Cao, Ruixin Ge, Yongqi Liu, Wei Pan, Miao Chen, Huijuan Liu, Chenghao Xuan et al. · 2026 · Journal of Controlled Release
Micellar LYTAC-engineered bionic coatings abrogate RANK-dependent osteocatabolism and boost fibrillogenesis-mimetic mineral accretion for empowering osteoporotic osseointegration
Youbo Zhao, Jie Zhou, Yi He, Yueting Ren, Jiayi Zhang, Maohua Chen, Zhong Yuan Luo, Zipeng Gong · 2026 · Bioactive Materials
A Versatile DNA‐Encoded Library Platform for the Discovery of Highly Cooperative Chemical Inducers of Proximity
Bingqi Tong, Sunny A. Tang, Yifan Deng, Zhihan Nan, Alison X. Gao, Gregory A. Michaud, Simone Bonazzi, Frédéric Berst, Frédéric J. Zécri, Shuang Liu et al. · 2026 · Advanced Science
Recent Advances in Nanotechnology for Targeted Protein Degradation
Mengchen Xu, Yi Yang, Jiajing Chen, Xi Wang, Shuyu Wang, Feihe Ma, Linqi Shi · 2026 · ACS Applied Materials & Interfaces
Alendronate-mineralized nanoparticles loaded with ALK-PROTAC reverse the resistance and rebound effects of ALK+ NSCLC to PROTAC therapy by disrupting the mitochondria-linked feedback
Jing Zhang, Liuqing Yang, Zhicheng Yan, Qinghua Wu, Xiaojia Jiao, Meifang Chen, Hua Zhang, Wenbing Dai, Xueqing Wang, Qiang Zhang et al. · 2026 · Asian Journal of Pharmaceutical Sciences
Surf2Spot: a surface-informed geometry-aware model for predicting partner-independent binder and nanobody design hotspots
Anwen Zhao, Yu Li, Zixuan Wang, Tianhao Wu, Ran Fu, Yuxuan Lou, Yanfen Xu, Xuliang Han, Wenying Wang, Jun Yan et al. · 2026 · Briefings in Bioinformatics
PROTACs in personalized and precision medicine: transforming targeted therapy with advances in selectivity and patient stratification
Sanket Nagmoti, Eshita Kadam, Nikhil S. Sakle, Harshad S. Kapare, Pawan N. Karwa · 2026 · Cancer Chemotherapy and Pharmacology
Proteoform-Resolved Interaction Mapping of Target Protein Complexes in Living Cells via Tracelessly Releasable Cross-Linking
Xue Yang, Bowen Zhong, Yue Sun, Baofeng Zhao, Lihua Zhang, Zhen Liang, Yukui Zhang, Liang Yu, Lihua Zhang · 2026 · Analytical Chemistry
Protein degraders targeting JAK/STAT3 signaling pathway are emerging therapeutic modalities for human cancers
Xinyu Feng, Nanjing Li, Xiaorong Chen, Xinyue Cao, Jingling Dai, Shaoquan Xiong, Zhu Yuan · 2026 · Biochemical Pharmacology
PROTAC-Loaded Nanoparticles Induce a “ROS Storm” through Targeted Degradation of GPX4 in Combination with a Mild Photothermal/Fenton-like Reaction for the Treatment of Triple-Negative Breast Cancer
Zekun Xu, Jinyu Wang, Xuhong Li, Tao Liao, Ying Kuang, Kai Wang, Cao Li · 2026 · ACS Applied Materials & Interfaces
Discovery of Tricyclic Oxazinoquinolinone-Based BCL6 PROTAC Degraders with Potent Activity Against Diffuse Large B-Cell Lymphoma
Xuetao Chen, Rujun Xu, Xiaoran Wang, Huidan Wu, Nan Wang, Xin Huang, Wenjing Kang, Qidong You, Xiaoke Guo, Zhengyu Jiang · 2026 · Journal of Medicinal Chemistry
Identification of selective FGFR2/4 degraders with potent antiproliferative activity
Jingyu Zhang, Xiaoying Zhang, Yan Li, Shuhan Jin, Bowen Liu, Yao Wu, Yiyang Pan, Gang Li, Chunwan Lu, Huanjie Shao et al. · 2026 · European Journal of Medicinal Chemistry
Discovery of Threonine Tyrosine Kinase (TTK) Degraders Utilizing an Electrophilic Monomethyl Fumarate Handle
Jian Zou, 孙要良, Beini Wen, Zihan Shi, Miao Sun, Yixuan Wang, Xinbo Wang, Lijie Lin, Shaofeng Zhang, Shuyao Zhang et al. · 2026 · Journal of Medicinal Chemistry
BindingDB Entry 50021764: Casitas b cell lymphoma‑B (Cbl-b): A new therapeutic avenue for small-molecule immunotherapy.
BindingDB · 2025 · UC San Diego
BindingDB Entry 50020161: Advances of bioorthogonal coupling reactions in drug development.
BindingDB · 2024 · UC San Diego
BindingDB Entry 50023674: Discovery of the first potent ROR1 degrader for the treatment of non-small cell lung cancer.
BindingDB · 2026 · UC San Diego
BindingDB Entry 50023713: MALT1 Inhibitors and Degraders: Strategies for NF-κB-Driven Malignancies.
BindingDB · 2026 · UC San Diego
BindingDB Entry 50023756: Discovery and Characterization of RP03707: A Highly Potent and Selective KRASG12D PROTAC.
BindingDB · 2026 · UC San Diego
BindingDB Entry 50022782: Modulating Phosphorylation by Proximity-Inducing Modalities for Cancer Therapy.
BindingDB · 2026 · UC San Diego
BindingDB Entry 50022106: Targeting kelch-like (KLHL) proteins: achievements, challenges and perspectives.
BindingDB · 2025 · UC San Diego
BindingDB Entry 50020673: Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degraders with
BindingDB · 2024 · UC San Diego
BindingDB Entry 50021145: Annual review of PROTAC degraders as anticancer agents in 2022.
BindingDB · 2025 · UC San Diego
BindingDB Entry 50023017: Discovery of the first selective and potent PROTAC degrader for the pseudokinase TRIB2.
BindingDB · 2026 · UC San Diego
BindingDB Entry 50021231: Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery.
BindingDB · 2025 · UC San Diego
BindingDB Entry 50020994: Facilitating the development of molecular glues: Opportunities from serendipity and rational design.
BindingDB · 2025 · UC San Diego
BindingDB Entry 50023673: Rational Design, Synthesis, and Biological Evaluation of Novel c-Met Degraders for Lung Cancer Therapy.
BindingDB · 2026 · UC San Diego
BindingDB Entry 50021852: Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment.
BindingDB · 2025 · UC San Diego
BindingDB Entry 50021125: Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection.
BindingDB · 2025 · UC San Diego
BindingDB Entry 50020221: Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).
BindingDB · 2024 · UC San Diego
BindingDB Entry 50021847: Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC).
BindingDB · 2025 · UC San Diego